InvestorNewsBreaks – TC BioPharm Holdings PLC (NASDAQ: TCBP) Advances Negotiations for Strategic Acquisitions in Cell Therapy
TC BioPharm (NASDAQ: TCBP), a clinical-stage biotech firm specializing in allogeneic gamma-delta T-cell therapies, announced progress in acquisition negotiations to enhance its therapeutic platform. The company is focusing on natural killer (“NK”) cell technologies and chimeric antigen receptor (“CAR”) technologies to expand into autoimmune diseases, solid tumors, and combination therapies. Its TCB008 therapeutic is being explored for CAR modification, leveraging its existing manufacturing capabilities. CEO…